Mark S. Graham

Array ( [id] => 9306035 [patent_doc_number] => 20140044709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-13 [patent_title] => 'TREATMENT OF HER2-POSITIVE CANCER WITH PACLITAXEL AND TRASTUZUMAB-MCC-DM1' [patent_app_type] => utility [patent_app_number] => 13/991580 [patent_app_country] => US [patent_app_date] => 2011-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 21402 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13991580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8094241 [patent_doc_number] => 20120082732 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-05 [patent_title] => 'MEDICINE FOR TREATMENT OF A CARCINOMA' [patent_app_type] => utility [patent_app_number] => 13/313664 [patent_app_country] => US [patent_app_date] => 2011-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 2198 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0082/20120082732.pdf [firstpage_image] =>[orig_patent_app_number] => 13313664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8171372 [patent_doc_number] => 20120107391 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-03 [patent_title] => 'THERAPY OF PLATINUM-RESISTANT CANCER' [patent_app_type] => utility [patent_app_number] => 13/309206 [patent_app_country] => US [patent_app_date] => 2011-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 32043 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0107/20120107391.pdf [firstpage_image] =>[orig_patent_app_number] => 13309206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11698834 [patent_doc_number] => 09688738 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-06-27 [patent_title] => 'Immunotherapy against ErbB-3 receptor' [patent_app_type] => utility [patent_app_number] => 13/882899 [patent_app_country] => US [patent_app_date] => 2011-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 21700 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 177 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13882899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11414387 [patent_doc_number] => 09561196 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-02-07 [patent_title] => 'Methods for evaluating and implementing prostate disease treatments' [patent_app_type] => utility [patent_app_number] => 13/230317 [patent_app_country] => US [patent_app_date] => 2011-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 21 [patent_no_of_words] => 20282 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13230317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10084509 [patent_doc_number] => 09121854 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-01 [patent_title] => 'Method for treating cancer or cancer metastasis' [patent_app_type] => utility [patent_app_number] => 13/137640 [patent_app_country] => US [patent_app_date] => 2011-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 9519 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13137640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8264712 [patent_doc_number] => 20120164141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-06-28 [patent_title] => 'METHODS AND COMPOSITIONS FOR INDUCING APOPTOSIS' [patent_app_type] => utility [patent_app_number] => 13/214916 [patent_app_country] => US [patent_app_date] => 2011-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 31412 [patent_no_of_claims] => 42 [patent_no_of_ind_claims] => 26 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13214916 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9232352 [patent_doc_number] => 08597654 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-12-03 [patent_title] => 'Adjuvant therapy with an anti-ERBB2 antibody conjugated to a maytansiniod' [patent_app_type] => utility [patent_app_number] => 13/205523 [patent_app_country] => US [patent_app_date] => 2011-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 31828 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13205523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8771956 [patent_doc_number] => 08425908 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-04-23 [patent_title] => 'Treatment with anti-ErbB2 antibodies' [patent_app_type] => utility [patent_app_number] => 13/185329 [patent_app_country] => US [patent_app_date] => 2011-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 17630 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13185329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8300994 [patent_doc_number] => 20120183552 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-19 [patent_title] => 'KIDNEY DISEASE TARGETS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/183696 [patent_app_country] => US [patent_app_date] => 2011-07-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42983 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13183696 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8950093 [patent_doc_number] => 20130195873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-01 [patent_title] => 'CARBOHYDRATE HAPTEN-BASED ANTI-CANCER VACCINES AND ANTIBODY DRUGS' [patent_app_type] => utility [patent_app_number] => 13/810199 [patent_app_country] => US [patent_app_date] => 2011-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 7027 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13810199 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7776296 [patent_doc_number] => 20120039885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-16 [patent_title] => 'COMPOSITION AND METHOD FOR CANCER TREATMENT' [patent_app_type] => utility [patent_app_number] => 13/151635 [patent_app_country] => US [patent_app_date] => 2011-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 13867 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0039/20120039885.pdf [firstpage_image] =>[orig_patent_app_number] => 13151635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7656360 [patent_doc_number] => 20110305629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-15 [patent_title] => 'Anti-Alpha v Beta 6 Antibodies and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 13/109168 [patent_app_country] => US [patent_app_date] => 2011-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 81 [patent_figures_cnt] => 81 [patent_no_of_words] => 81504 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0305/20110305629.pdf [firstpage_image] =>[orig_patent_app_number] => 13109168 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7566940 [patent_doc_number] => 20110287003 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-24 [patent_title] => 'TREATMENT METHODS' [patent_app_type] => utility [patent_app_number] => 13/108899 [patent_app_country] => US [patent_app_date] => 2011-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 35111 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 13 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0287/20110287003.pdf [firstpage_image] =>[orig_patent_app_number] => 13108899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8127415 [patent_doc_number] => 20120088255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-12 [patent_title] => 'HER-2 BINDING ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 13/103888 [patent_app_country] => US [patent_app_date] => 2011-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 11800 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0088/20120088255.pdf [firstpage_image] =>[orig_patent_app_number] => 13103888 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8532934 [patent_doc_number] => 08309087 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-11-13 [patent_title] => 'Treatment with anti-ErbB2 antibodies' [patent_app_type] => utility [patent_app_number] => 13/103799 [patent_app_country] => US [patent_app_date] => 2011-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 2 [patent_no_of_words] => 17575 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13103799 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8312610 [patent_doc_number] => 20120189634 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-26 [patent_title] => 'TACI AS AN ANTI-TUMOR AGENT' [patent_app_type] => utility [patent_app_number] => 13/044317 [patent_app_country] => US [patent_app_date] => 2011-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 9374 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13044317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10580962 [patent_doc_number] => 09303081 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-04-05 [patent_title] => 'Recombinant production of mixtures of antibodies' [patent_app_type] => utility [patent_app_number] => 12/932719 [patent_app_country] => US [patent_app_date] => 2011-03-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 36 [patent_no_of_words] => 33969 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12932719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6087887 [patent_doc_number] => 20110217297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-08 [patent_title] => 'METHODS FOR CLASSIFYING AND TREATING BREAST CANCERS' [patent_app_type] => utility [patent_app_number] => 13/040042 [patent_app_country] => US [patent_app_date] => 2011-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 60 [patent_no_of_words] => 41006 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0217/20110217297.pdf [firstpage_image] =>[orig_patent_app_number] => 13040042 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11408957 [patent_doc_number] => 09556249 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-01-31 [patent_title] => 'Neuregulin antagonists and use thereof in treating cancer' [patent_app_type] => utility [patent_app_number] => 13/029199 [patent_app_country] => US [patent_app_date] => 2011-02-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 19 [patent_no_of_words] => 29580 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13029199 [rel_patent_id] =>[rel_patent_doc_number] =>)